Zoono Group Limited (ZNO) AI Stock Analysis

• Market Cap: AU$22.34M
• Dividend Yield: N/A
• Average Volume (3M): 153.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.68
• Revenue Growth: 17.41%
• EPS Growth: 67.94%
• Country: AU
• Employees: 2
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 406,211,760
• 10 Day Avg. Volume: 257,173
• 30 Day Avg. Volume: 153,260
• PEG Ratio: 0.04
• Price to Book (P/B): 3.62
• Price to Sales (P/S): 9.30
• P/FCF Ratio: -6.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: AU$0.05 ▼(-38.75% Downside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held down primarily by weak financial performance—deep losses, negative margins, and ongoing cash burn alongside equity erosion. Technicals also point to a weak downtrend (below key moving averages with negative MACD), partially offset by oversold RSI conditions. Valuation is difficult to support because earnings are negative and no dividend yield is provided.

Positive Factors

Low leverage

Low reported leverage (debt-to-equity ~0.18) materially reduces immediate solvency risk and gives the firm financial flexibility versus highly levered peers. Over 2–6 months this lowers default risk and preserves optionality for refinancing, partnerships or targeted investment to support a recovery plan.

Antimicrobial product focus

A focused product franchise in antimicrobial surface and skin applications addresses durable hygiene and infection-control needs across consumer, institutional and commercial channels. Structural demand and repeat consumption create a platform for recurring revenue if distribution and cost structures scale sustainably.

FY2025 revenue growth

Sequential top-line growth (+14.8% FY2025) demonstrates the company can regain sales momentum despite prior volatility. In a 2–6 month horizon, continued revenue expansion is a prerequisite for leveraging fixed costs, improving gross margins, and proving product-market fit to support a path toward sustainable profitability.

Negative Factors

Deep losses & negative margins

Very large negative net margins (around -314%) indicate structural unprofitability rather than a timing or seasonal issue. Persistent deeply negative margins erode capital, undermine reinvestment capacity, and mean the company must materially improve pricing, mix or cost structure to reach sustainable earnings over the medium term.

Persistent negative cash flow

Chronic negative operating cash flow across multiple years forces reliance on external financing or equity dilution to fund operations. This persistent cash burn reduces runway, constrains the ability to invest in distribution or manufacturing scale, and raises medium-term financing and dilution risk.

Material equity erosion

Substantial decline in shareholders' equity over several years weakens the balance-sheet buffer against shocks and limits borrowing capacity. Ongoing erosion constrains strategic options, investor confidence and the firm’s ability to absorb further losses while executing a recovery or growth strategy.

Zoono Group Limited Business Overview & Revenue Model

Company Description

Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products in New Zealand and internationally. The company's products include hand sanitizers, textile applicators, mould remediation, and surface sanitizers. It serves airlines, healthcare, childcare, facilities management, transportation, education, and hospitality sectors. The company was incorporated in 1986 and is headquartered in Auckland, New Zealand.

How the Company Makes Money

Zoono Group Limited primarily generates revenue through the sale of its antimicrobial products to various markets, including healthcare, hospitality, transportation, and consumer sectors. The company's revenue streams include direct sales to businesses and consumers, as well as partnerships and distribution agreements with third-party companies that extend its market reach. Zoono's earnings are bolstered by its ability to secure significant contracts and partnerships with organizations seeking effective antimicrobial solutions. Additionally, the company invests in research and development to enhance its product offerings and adapt to emerging market needs, which can contribute to increased sales and market presence.

Zoono Group Limited Financial Statement Overview

Summary

Overall fundamentals are stressed: revenue is small (~A$1.16M in FY2025) and profitability remains deeply negative (net margin ~-314%) with multi-year losses. Cash flow is persistently negative (FY2025 operating cash flow ~-A$1.58M) and equity has eroded materially over time, though low leverage (debt-to-equity ~0.18) reduces immediate solvency risk.

Income Statement

Profitability has deteriorated sharply versus earlier years. Revenue in FY2025 rose to ~A$1.16M (+14.8% YoY), but the company remains deeply loss-making with negative gross profit and very weak operating profitability (FY2025 net margin about -314%). Results have been volatile: strong profits in FY2020–FY2021 were followed by multi-year losses and structurally depressed margins, indicating an unproven path back to sustainable earnings.

Balance Sheet

Leverage is low, with FY2025 debt of ~A$0.54M against equity of ~A$2.97M (debt-to-equity ~0.18), which reduces solvency risk. However, equity has fallen materially over time (from ~A$19.6M in FY2020 to ~A$3.0M in FY2025) and returns on equity are strongly negative in recent years, reflecting ongoing losses eroding the capital base.

Cash Flow

Cash generation is weak and consistently negative. Operating cash flow was negative in each of the last four fiscal years, including ~-A$1.58M in FY2025, with free cash flow also negative and declining (~-36% YoY). While cash burn improved versus FY2024, the business is still funding operations from sources other than internally generated cash, which raises financing and dilution risk if losses persist.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	950.69K	1.16M	960.30K	3.07M	8.13M	25.22M
Gross Profit	-709.17K	-281.53K	-4.36M	-625.33K	2.10M	11.88M
EBITDA	-3.07M	-3.26M	-7.89M	-181.62K	-5.11M	5.89M
Net Income	-3.51M	-3.64M	-8.30M	-321.97K	-10.28M	4.40M
Balance Sheet
Total Assets	6.01M	5.87M	9.01M	13.40M	17.68M	29.46M
Cash, Cash Equivalents and Short-Term Investments	475.33K	47.30K	1.79M	759.99K	3.30M	4.55M
Total Debt	625.70K	544.56K	726.63K	868.99K	1.00M	1.93M
Total Liabilities	2.53M	2.89M	2.76M	3.24M	8.41M	9.88M
Stockholders Equity	3.47M	2.97M	6.24M	10.16M	10.00M	19.68M
Cash Flow
Free Cash Flow	-1.76M	-1.58M	-2.89M	-3.55M	-996.61K	834.07K
Operating Cash Flow	-1.76M	-1.58M	-2.89M	-3.55M	-974.11K	1.38M
Investing Cash Flow	0.00	0.00	-58.73K	-53.49K	-107.62K	-1.26M
Financing Cash Flow	1.50M	-190.15K	3.99M	873.62K	-54.99K	-4.82M

Zoono Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZNO, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 31.62 is Neutral, neither overbought nor oversold. The STOCH value of 29.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ZNO.

Zoono Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
SKN	45 Neutral	AU$18.00M	-0.26	―	―	12.92%	34.21%
ZNO	44 Neutral	AU$22.34M	-7.05	-77.92%	―	17.41%	67.94%
NGS	42 Neutral	AU$6.66M	-0.01	―	―	-21.84%	79.99%
CCO	37 Underperform	AU$9.18M	-1.73	-555.97%	―	88.48%	51.61%

Zoono Group Limited Corporate Events

Zoono Releases Interim Financial Report for Half-Year Ended 31 December 2025

Zoono Group Limited has released its interim financial report and ASX Appendix 4D for the half-year ended 31 December 2025. The document provides condensed financial statements, directors’ commentary, auditor review information and other statutory disclosures, and is intended to be read alongside the company’s 30 June 2025 annual report and prior continuous disclosures under Australian corporate and listing regulations.

The most recent analyst rating on (AU:ZNO) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Zoono Group Limited stock, see the AU:ZNO Stock Forecast page.

Zoono Clarifies Compliance Status of Planned Share Placement in Appendix 3B Update

Zoono Group Limited has updated its previously announced proposed issue of securities, clarifying that the share recipient was not a related party or other person captured under ASX Listing Rule 10.11 when the agreement to issue the shares was made. This clarification is part of an amended Appendix 3B filing concerning a placement or other type of security issue, and is intended to confirm compliance with ASX requirements around approvals and related-party transactions, reducing potential governance concerns for investors.

The company reaffirmed that the proposed securities will be quoted on the ASX in line with standard procedures, with final issuance details to be notified once confirmed under a separate Appendix 2A. By tightening the disclosure around the nature of the recipient and regulatory treatment of the placement, Zoono aims to provide greater transparency to the market and ensure that stakeholders understand that additional shareholder approvals under Listing Rule 10.11 are not required for this transaction.

The most recent analyst rating on (AU:ZNO) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Zoono Group Limited stock, see the AU:ZNO Stock Forecast page.

Zoono Appoints New Director With Performance-Linked Share Incentive

Zoono Group Limited has appointed Marc Braterman as a director effective 3 February 2026, with disclosures confirming that he currently holds no shares or indirect security interests in the company. The filing outlines that, in his role as CEO of OSY Group Limited, Braterman has a long-term incentive arrangement granting rights to acquire up to 5 million Zoono fully paid ordinary shares at nil consideration in three performance-based tranches tied to escalating gross sales targets in New Zealand dollars, signaling a focus on growth-driven executive alignment that may influence the company’s future performance and governance dynamics.

The most recent analyst rating on (AU:ZNO) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Zoono Group Limited stock, see the AU:ZNO Stock Forecast page.

Zoono Defends ASX Disclosure and Flags Slow but Building OSY-Linked Revenues

Zoono Group Limited has responded to an ASX price query by outlining how it monitors and discloses its dealings under its exclusive agency agreement with OSY Group, stressing that it remains fully compliant with continuous disclosure obligations and maintains detailed visibility over trials, negotiations and customer orders. While the company has begun to receive small, non-material orders under the OSY agreement in FY26 and has secured exclusive packaging contracts in the UK, South Africa and Australia, it confirmed that no OSY-related revenue was recorded in FY25 and that minimum sales benchmarks in key regions have not yet been met due to slower-than-expected adoption by major UK supermarket chains, rather than any failure of the technology or the partners; nonetheless, Zoono is continuing the OSY arrangement, expects orders to build over FY26 toward agreed targets, and has reaffirmed that it will update the market if material orders are received.